Lexaria Bioscience Croissance future
Future contrôle des critères 2/6
Lexaria Bioscience is forecast to grow earnings and revenue by 49.1% and 62.6% per annum respectively while EPS is expected to grow by 48.7% per annum.
Informations clés
49.1%
Taux de croissance des bénéfices
48.7%
Taux de croissance du BPA
Pharmaceuticals croissance des bénéfices | 23.7% |
Taux de croissance des recettes | 62.6% |
Rendement futur des capitaux propres | n/a |
Couverture par les analystes | Low |
Dernière mise à jour | 23 Jul 2024 |
Mises à jour récentes de la croissance future
Recent updates
Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
8/31/2027 | 4 | -17 | N/A | N/A | 1 |
8/31/2026 | 1 | -9 | N/A | N/A | 2 |
8/31/2025 | 1 | -7 | N/A | -4 | 3 |
8/31/2024 | 0 | -5 | N/A | -3 | 3 |
5/31/2024 | 0 | -5 | -5 | -5 | N/A |
2/29/2024 | 0 | -5 | -5 | -5 | N/A |
11/30/2023 | 0 | -6 | -6 | -6 | N/A |
8/31/2023 | 0 | -7 | -6 | -6 | N/A |
5/31/2023 | 0 | -7 | -6 | -5 | N/A |
2/28/2023 | 0 | -7 | -5 | -5 | N/A |
11/30/2022 | 0 | -7 | -5 | -5 | N/A |
8/31/2022 | 0 | -7 | -5 | -5 | N/A |
5/31/2022 | 0 | -7 | -5 | -5 | N/A |
2/28/2022 | 0 | -7 | -5 | -5 | N/A |
11/30/2021 | 0 | -7 | -5 | -4 | N/A |
8/31/2021 | 1 | -6 | -4 | -4 | N/A |
5/31/2021 | 1 | -5 | -4 | -3 | N/A |
2/28/2021 | 1 | -4 | -3 | -3 | N/A |
11/30/2020 | 1 | -4 | -3 | -3 | N/A |
8/31/2020 | 0 | -4 | -3 | -3 | N/A |
5/31/2020 | 0 | -4 | -3 | -3 | N/A |
2/29/2020 | 0 | -4 | -3 | -3 | N/A |
11/30/2019 | 0 | -4 | -4 | -3 | N/A |
8/31/2019 | 0 | -4 | -4 | -3 | N/A |
5/31/2019 | 0 | -4 | -4 | -3 | N/A |
2/28/2019 | 0 | -6 | -3 | -3 | N/A |
11/30/2018 | 0 | -7 | -3 | -3 | N/A |
8/31/2018 | 0 | -7 | -3 | -3 | N/A |
5/31/2018 | 0 | -6 | -2 | -2 | N/A |
2/28/2018 | 0 | -3 | N/A | -2 | N/A |
11/30/2017 | 0 | -2 | N/A | -2 | N/A |
8/31/2017 | 0 | -2 | N/A | -2 | N/A |
5/31/2017 | 0 | -1 | N/A | -1 | N/A |
2/28/2017 | 0 | -1 | N/A | -1 | N/A |
11/30/2016 | 0 | -1 | N/A | -1 | N/A |
8/31/2016 | 0 | -1 | N/A | -1 | N/A |
5/31/2016 | 0 | -1 | N/A | -1 | N/A |
2/29/2016 | 0 | -2 | N/A | -1 | N/A |
11/30/2015 | 0 | -2 | N/A | -2 | N/A |
8/31/2015 | 0 | -2 | N/A | -2 | N/A |
5/31/2015 | 0 | -2 | N/A | -1 | N/A |
2/28/2015 | 0 | -2 | N/A | -1 | N/A |
11/30/2014 | N/A | -2 | N/A | -1 | N/A |
8/31/2014 | N/A | -2 | N/A | -1 | N/A |
7/31/2014 | 1 | -1 | N/A | 0 | N/A |
4/30/2014 | 1 | -1 | N/A | 0 | N/A |
1/31/2014 | 1 | 0 | N/A | 0 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: LEXX is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: LEXX is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: LEXX is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: LEXX's revenue (62.6% per year) is forecast to grow faster than the US market (8.9% per year).
Croissance élevée des revenus: LEXX's revenue (62.6% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if LEXX's Return on Equity is forecast to be high in 3 years time